The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy

被引:0
|
作者
Liu, Tao [1 ]
Zhou, Ping [2 ]
Jiang, Xin [3 ]
Wang, Na [1 ]
Shou, Jialing [1 ]
Fang, Yuqiang [1 ,4 ]
机构
[1] Army Med Univ, Chongqing Inst Cardiol, Daping Hosp, Dept Cardiol, Chongqing, Peoples R China
[2] First Peoples Hosp Chongqing Liang Jiang New Area, Dept Cardiol, Chongqing 401121, Peoples R China
[3] Peoples Hosp Chongqing Da Du Kou Area, Dept Cardiol, Chongqing, Peoples R China
[4] Army Med Univ, Dept Cardiol, Chongqing Inst Cardiol, Daping Hosp, 10 Changjiang Branch Rd, Chongqing 400042, Peoples R China
来源
JOURNAL OF RESEARCH IN MEDICAL SCIENCES | 2023年 / 28卷 / 01期
基金
中国国家自然科学基金;
关键词
Angiotensin receptor blockers; angiotensin-converting enzyme inhibitors; beta-blockers; dilated cardiomyopathy; PREDICTORS; THERAPY; PREVALENCE; RECOVERY; INSIGHTS;
D O I
10.4103/jrms.jrms_626_21
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Whether combination administration of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs) has a "reversal" effect on cardiac structure and function for first-diagnosed idiopathic dilated cardiomyopathy (FSIDCM) patients with unclear etiologies and inducements is unknown. Materials and Methods: We studied the effect of the protocol on FSIDCM patients. The effect was investigated in 26 FSIDCM patients. The criteria of "complete reversal" included left ventricular end-diastolic diameter (LVEDD)<= 50 mm for females or <= 55 mm for males and left ventricular ejection fraction (LVEF) >= 45%; the criteria of "partial reversal" was the decreased rate of LVEDD (Delta LVEDD) >10% or the increase rate of LVEF (Delta LVEF) >10%; the criteria of "no reversal" included LVEDD >50 mm for females or >55 mm for males and Delta LVEDD <10%, and LVEF <45% and Delta LVEF <10%. Results: Within the follow-up period, nine patients showed "complete reversal," eight "partial reversal," and nine "no reversal." Improvements in echocardiogram parameters were the most significant in "complete reversal" patients (P < 0.001), followed by "partial reversal" and "no reversal" patients (P < 0.05). The QRS (Q wave, R wave, S wave) duration and symptoms duration in "complete reversal" patients were the shortest, followed by "partial reversal" and "no reversal" patients. Conclusion: ACEIs or ARBs and BBs have a "complete reversal" effect on the left ventricular size and function of some FSIDCM patients. Patients with a narrow QRS and short symptom duration may have a good response.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis
    Raimondi, Sara
    Botteri, Edoardo
    Munzone, Elisabetta
    Cipolla, Carlo
    Rotmensz, Nicole
    DeCensi, Andrea
    Gandini, Sara
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (01) : 212 - 219
  • [2] The Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Is Associated with the Recovered Ejection Fraction in Patients with Dilated Cardiomyopathy
    Enzan, Nobuyuki
    Matsushima, Shouji
    Ide, Tomomi
    Kaku, Hidetaka
    Tohyama, Takeshi
    Funakoshi, Kouta
    Higo, Taiki
    Tsutsui, Hiroyuki
    INTERNATIONAL HEART JOURNAL, 2021, 62 (04) : 801 - 810
  • [3] Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy
    Matsumura, Yoshihisa
    Hoshikawa-Nagai, Eri
    Kubo, Toru
    Yamasaki, Naohito
    Kitaoka, Hiroaki
    Takata, Jun
    Doi, Yoshinori
    Sugiura, Tetsuro
    CARDIOVASCULAR ULTRASOUND, 2015, 13
  • [4] Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice
    Barrios, Vivencio
    Coca, Antonio
    Escobar, Carlos
    Enrique, Rosa
    Miguel Rincon, Luis
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (02) : 159 - 166
  • [5] Efficacy of Beta-Blockers and Angiotensin-Converting Enzyme Inhibitors in Non-Ischemic Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis
    Llerena-Velastegui, Jordan
    Santamaria-Lasso, Melisa
    Mejia-Mora, Melany
    Santander-Aldean, Mauricio
    Granda-Munoz, Andrea
    Hurtado-Alzate, Claudia
    de Jesus, Ana Clara Fonseca Souza
    Baldelomar-Ortiz, Jurgen
    CARDIOLOGY RESEARCH, 2024, 15 (04) : 281 - 297
  • [6] Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for the Prevention of Migraines
    Gales, Barry J.
    Bailey, Emilee K.
    Reed, Ashley N.
    Gales, Mark A.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (02) : 360 - 366
  • [7] Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children
    Vaz de Castro, Pedro Alves Soares
    Bitencourt, Leticia
    Pereira, Bruno Wilnes Simas
    Lima, Ananda Queiroz Rocha
    Hermida, Henrique Santos
    Moreira Neto, Carlos Roberto
    Mestriner, Mariana Dinamarco
    Simoes e Silva, Ana Cristina
    PEDIATRIC NEPHROLOGY, 2022, 37 (03) : 499 - 508
  • [8] Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation
    Anis, Rafik R.
    EXPERIMENTAL & CLINICAL CARDIOLOGY, 2009, 14 (01) : E1 - E7
  • [9] Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
    Xiao-Long Li
    Tao Li
    Qi-Cong Du
    Li Yang
    Kun-Lun He
    World Journal of Clinical Cases, 2021, 9 (20) : 5462 - 5469
  • [10] Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
    Li, Xiao-Long
    Li, Tao
    Du, Qi-Cong
    Yang, Li
    He, Kun-Lun
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (20) : 5462 - 5469